A look behind the scenes: The risk and pathogenesis of primary osteoporosis

Nature Reviews Rheumatology

Volumn 11, Issue 8, 2015, Pages 462-474

  Hendrickx, Gretl ^a   Boudin, Eveline ^a   Van Hul, Wim ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BLOSOZUMAB; CATHEPSIN K; DENOSUMAB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN P53; PROTEIN P66; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ROMOSOZUMAB; SEX HORMONE; TRANSCRIPTION FACTOR FOXO;

AGING; APOPTOSIS; BONE DENSITY; BONE MASS; DNA METHYLATION; EPIGENETICS; FRACTURE; GENETIC ASSOCIATION; HEREDITY; HORMONE DEFICIENCY; HUMAN; JUVENILE OSTEOPOROSIS; LIFESTYLE; MACROAUTOPHAGY; MONOGENIC DISORDER; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; DEFICIENCY; GENETICS;

APOPTOSIS; GONADAL STEROID HORMONES; HUMANS; LIFE STYLE; OSTEOPOROSIS; OXIDATIVE STRESS; RISK FACTORS;

EID: 84938422411     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.48     Document Type: Review

References (150)

1. Abrahamsen, B., van Staa, T., Ariely, R., Olson, M. & Cooper, C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos. Int. 20, 1633-1650 (2009).
2. van den Bergh, J. P., van Geel, T. A. & Geusens, P. P. Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat. Rev. Rheumatol. 8, 163-172 (2012).
3. Melton, L. J. 3rd. How many women have osteoporosis now? J. Bone Miner. Res. 10, 175-177 (1995).
4. Randell, A., et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos. Int. 5, 427-432 (1995).
5. Kanis, J. A. & Johnell, O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos. Int. 16, 229-238 (2005).
6. Bachrach, L. K. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol. Metab. 12, 22-28 (2001).
7. Sapir-Koren, R. & Livshits, G. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? Osteoporos. Int. (2014).
8. Zuo, C., et al. Osteoblastogenesis regulation signals in bone remodeling. Osteoporos. Int. 23, 1653-1663 (2012).
9. Garnero, P. The contribution of collagen crosslinks to bone strength. Bonekey Rep. 1, 182 (2012).
10. Alliston, T. Biological regulation of bone quality. Curr. Osteoporos. Rep. 12, 366-375 (2014).
11. Sroga, G. E. & Vashishth, D. Effects of bone matrix proteins on fracture and fragility in osteoporosis. Curr. Osteoporos. Rep. 10, 141-150 (2012).
12. Bouxsein, M. L. & Karasik, D. Bone geometry and skeletal fragility. Curr. Osteoporos. Rep. 4, 49-56 (2006).
13. Almeida, M. Aging mechanisms in bone. Bonekey Rep. 1, 102 (2012).
14. Manolagas, S. C. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31, 266-300 (2010).
15. de Boer, J., et al. Premature aging in mice deficient in DNA repair and transcription. Science 296, 1276-1279 (2002).
16. Tyner, S. D., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53 (2002).
17. Nojiri, H., et al. Cytoplasmic superoxide causes bone fragility owing to low-turnover osteoporosis and impaired collagen cross-linking. J. Bone Miner. Res. 26, 2682-2694 (2011).
18. Smietana, M. J., Arruda, E. M., Faulkner, J. A., Brooks, S. V. & Larkin, L. M. Reactive oxygen species on bone mineral density and mechanics in Cu, Zn superoxide dismutase (Sod1) knockout mice. Biochem. Biophys. Res. Commun. 403, 149-153 (2010).
19. Ambrogini, E., et al. FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab. 11, 136-146 (2010).
20. Almeida, M. Unraveling the role of FoxOs in bone-insights from mouse models. Bone 49, 319-327 (2011).
21. Almeida, M., Han, L., Martin-Millan, M., OBrien, C. A. & Manolagas, S. C. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor-to forkhead box O-mediated transcription. J. Biol. Chem. 282, 27298-27305 (2007).
22. Essers, M. A., et al. Functional interaction between β-catenin and FOXO in oxidative stress signaling. Science 308, 1181-1184 (2005).
23. Migliaccio, E., et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 402, 309-313 (1999).
24. Nemoto, S. & Finkel, T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295, 2450-2452 (2002).
25. Giorgio, M., et al. Electron. transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 122, 221-233 (2005).
26. Pacini, S., et al. p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. Mol. Cell Biol. 24, 1747-1757 (2004).
27. Bartell, S. M., et al. Deletion of the redox amplifier p66shc decreases ROS production in murine bone and increases osteoblast resistance to oxidative stress and bone mass [abstract]. J. Bone Miner. Res. 26 (Suppl. 1), S85 (2011).
28. Maier, B., et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306-319 (2004).
29. Wang, X., et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J. Cell Biol. 172, 115-125 (2006).
30. Jilka, R. L., et al. Dysfunctional osteocytes increase RANKL and promote cortical pore formation in their vicinity: a mechanistic explanation for the development of cortical porosity with age [abstract]. J. Bone Miner. Res. 27 (Suppl. 1), S348 (2012).
31. Jilka, R. L., et al. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates bone porosity with age. J. Bone Miner. Res. 29, 103-117 (2014).
32. Tomkinson, A., Gevers, E. F., Wit, J. M., Reeve, J. & Noble, B. S. The role of estrogen in the control of rat osteocyte apoptosis. J. Bone Miner. Res. 13, 1243-1250 (1998).
33. Almeida, M., et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J. Biol. Chem. 282, 27285-27297 (2007).
34. Tomkinson, A., Reeve, J., Shaw, R. W. & Noble, B. S. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 82, 3128-3135 (1997).
35. Frost, H. M. Micropetrosis. J. Bone Joint Surg. Am. 42-A, 144-150 (1960).
36. Busse, B., et al. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell 9, 1065-1075 (2010).
37. Carpentier, V. T., et al. Increased proportion of hypermineralized osteocyte lacunae in osteoporotic and osteoarthritic human trabecular bone: implications for bone remodeling. Bone 50, 688-694 (2012).
38. Manolagas, S. C., OBrien, C. A. & Almeida, M. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 9, 699-712 (2013).
39. Seeman, E. Periosteal bone formation-a neglected determinant of bone strength. N. Engl. J. Med. 349, 320-323 (2003).
40. Martin-Millan, M., et al. The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol. Endocrinol. 24, 323-334 (2010).
41. Nakamura, T., et al. Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell 130, 811-823 (2007).
42. Chiang, C., et al. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J. Bone Miner. Res. 24, 621-631 (2009).
43. Notini, A. J., et al. Osteoblast deletion of exon 3 of the androgen receptor gene results in trabecular bone loss in adult male mice. J. Bone Miner. Res. 22, 347-356 (2007).
44. Sinnesael, M., et al. Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes. J. Bone Miner. Res. 27, 2535-2543 (2012).
45. Almeida, M., et al. Estrogens attenuate oxidative stress and the differentiation and apoptosis of osteoblasts by DNA-binding-independent actions of the ERα. J. Bone Miner. Res. 25, 769-781 (2010).
46. Kousteni, S., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-730 (2001).
47. Kousteni, S., et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298, 843-846 (2002).
48. Marathe, N., Rangaswami, H., Zhuang, S., Boss, G. R. & Pilz, R. B. Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. J. Biol. Chem. 287, 978-988 (2012).
49. Seeman, E. Pathogenesis of bone fragility in women and men. Lancet 359, 1841-1850 (2002).
50. Kaufman, J. M. & Vermeulen, A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833-876 (2005).
51. Shahnazari, M., et al. Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice. Bone 50, 628-637 (2012).
52. Syed, F. A., et al. Effects of chronic estrogen treatment on modulating age-related bone loss in female mice. J. Bone Miner. Res. 25, 2438-2446 (2010).
53. Zebaze, R. M., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375, 1729-1736 (2010).
54. Manolagas, S. C. & Parfitt, A. M. For whom the bell tolls: distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases. Bone 54, 272-278 (2013).
55. Hocking, L. J., Whitehouse, C. & Helfrich, M. H. Autophagy: a new player in skeletal maintenance? J. Bone Miner. Res. 27, 1439-1447 (2012).
56. Kim, K. H. & Lee, M. S. Autophagy-a key player in cellular and body metabolism. Nat. Rev. Endocrinol. 10, 322-337 (2014).
57. Zhang, L., et al. Pathway-based genome-wide association analysis identified the importance of regulation-of-autophagy pathway for ultradistal radius BMD. J. Bone Miner. Res. 25, 1572-1580 (2010).
58. Rubinsztein, D. C., Marino, G. & Kroemer, G. Autophagy and aging. Cell 146, 682-695 (2011).
59. Selman, C., et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326, 140-144 (2009).
60. Chang, Y. Y., et al. Nutrient-dependent regulation of autophagy through the target of rapamycin pathway. Biochem. Soc. Trans. 37, 232-236 (2009).
61. DeSelm, C. J., et al. Autophagy proteins regulate the secretory component of osteoclastic bone resorption. Dev. Cell 21, 966-974 (2011).
62. Liu, F., et al. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J. Bone Miner. Res. 28, 2414-2430 (2013).
63. Onal, M., et al. Suppression of autophagy in osteocytes mimics skeletal aging. J. Biol. Chem. 288, 17432-17440 (2013).
64. Bonjour, J. P., Kraenzlin, M., Levasseur, R., Warren, M. & Whiting, S. Dairy in adulthood: from foods to nutrient interactions on bone and skeletal muscle health. J. Am. Coll. Nutr. 32, 251-263 (2013).
65. Christodoulou, S., Goula, T., Ververidis, A. & Drosos, G. Vitamin D and bone disease. Biomed. Res. Int. 2013, 396541 (2013).
66. Eisman, J. A. & Bouillon, R. Vitamin D: direct effects of vitamin D metabolites on bone: lessons from genetically modified mice. Bonekey Rep. 3, 499 (2014).
67. Rajendran, P., et al. Antioxidants and human diseases. Clin. Chim. Acta 436C, 332-347 (2014).
68. Shen, C. L., et al. Fruits and dietary phytochemicals in bone protection. Nutr. Res. 32, 897-910 (2012).
69. Li, J. J., et al. Fruit and vegetable intake and bone mass in Chinese adolescents, young and postmenopausal women. Public Health Nutr. 16, 78-86 (2013).
70. New, S. A., et al. Dietary influences on bone mass and bone metabolism: further evidence of a positive link between fruit and vegetable consumption and bone health? Am. J. Clin. Nutr. 71, 142-151 (2000).
71. Prynne, C. J., et al. Fruit and vegetable intakes and bone mineral status: a cross sectional study in 5 age and sex cohorts. Am. J. Clin. Nutr. 83, 1420-1428 (2006).
72. Zalloua, P. A., et al. Impact of seafood and fruit consumption on bone mineral density. Maturitas 56, 1-11 (2007).
73. Heaney, R. P. & Layman, D. K. Amount and type of protein influences bone health. Am. J. Clin. Nutr. 87, 1567S-1570S (2008).
74. Sebastian, A. Dietary protein content and the diets net acid load: opposing effects on bone health. Am. J. Clin. Nutr. 82, 921-922 (2005).
75. Bonjour, J. P. Nutritional disturbance in acid-base balance and osteoporosis: a hypothesis that disregards the essential homeostatic role of the kidney. Br. J. Nutr. 110, 1168-1177 (2013).
76. Bushinsky, D. A. Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. Am. J. Physiol. 271, F216-F222 (1996).
77. Leeuwenburgh, C. & Heinecke, J. W. Oxidative stress and antioxidants in exercise. Curr. Med. Chem. 8, 829-838 (2001).
78. Ozcivici, E., et al. Mechanical signals as anabolic agents in bone. Nat. Rev. Rheumatol. 6, 50-59 (2010).
79. Rochefort, G. Y., Pallu, S. & Benhamou, C. L. Osteocyte: the unrecognized side of bone tissue. Osteoporos. Int. 21, 1457-1469 (2010).
80. Balemans, W., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum. Mol. Genet. 10, 537-543 (2001).
81. Balemans, W., et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91-97 (2002).
82. Li, X., et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883-19887 (2005).
83. Semenov, M., Tamai, K. & He, X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770-26775 (2005).
84. Boudin, E., Fijalkowski, I., Piters, E. & Van Hul, W. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin. Arthritis Rheum. 43, 220-240 (2013).
85. Wang, Y., et al. Wnt and the Wnt signaling pathway in bone development and disease. Front. Biosci. (Landmark Ed.) 19, 379-407 (2014).
86. Maurel, D. B., Boisseau, N., Benhamou, C. L. & Jaffre, C. Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 23, 1-16 (2012).
87. Ronis, M. J., Mercer, K. & Chen, J. R. Effects of nutrition and alcohol consumption on bone loss. Curr. Osteoporos. Rep. 9, 53-59 (2011).
88. Chen, J. R., et al. A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt/β-catenin signaling. J. Bone Miner. Res. 25, 1117-1127 (2010).
89. Chen, J. R., Shankar, K., Nagarajan, S., Badger, T. M. & Ronis, M. J. Protective effects of estradiol on ethanol-induced bone loss involve inhibition of reactive oxygen species generation in osteoblasts and downstream activation of the extracellular signal-regulated kinase/signal transducer and activator of transcription 3/receptor activator of nuclear factor-?B ligand signaling cascade. J. Pharmacol. Exp. Ther. 324, 50-59 (2008).
90. Kanis, J. A., et al. Smoking and fracture risk: a meta-analysis. Osteoporos. Int. 16, 155-162 (2005).
91. Ward, K. D. & Klesges, R. C. A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif. Tissue Int. 68, 259-270 (2001).
92. Yoon, V., Maalouf, N. M. & Sakhaee, K. The effects of smoking on bone metabolism. Osteoporos. Int. 23, 2081-2092 (2012).
93. Marini, J. C. & Blissett, A. R. New genes in bone development: whats new in osteogenesis imperfecta. J. Clin. Endocrinol. Metab. 98, 3095-3103 (2013).
94. Sillence, D. O., Senn, A. & Danks, D. M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16, 101-116 (1979).
95. OMIM® Online Mendelian Inheritance in Man®. An Online Catalog of Human Genes and Genetic Disorders [online], http://www.omim.org (2015).
96. Van Dijk, F. S. & Sillence, D. O. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am. J. Med. Genet. A 164, 1470-1481 (2014).
97. Lazarus, S., Zankl, A. & Duncan, E. L. Next-generation sequencing: a frameshift in skeletal dysplasia gene discovery. Osteoporos. Int. 25, 407-422 (2014).
98. Warman, M. L., et al. Nosology and classification of genetic skeletal disorders: 2010 revision. Am. J. Med. Genet. A 155A, 943-968 (2011).
99. van Dijk, F. S., et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur. J. Hum. Genet. 20, 11-19 (2012).
100. Lazarus, S., Moffatt, P., Duncan, E. L. & Thomas, G. P. A brilliant breakthrough in OI type V. Osteoporos. Int. 25, 399-405 (2014).
101. Eyre, D. R. & Weis, M. A. Bone collagen: new clues to its mineralization mechanism from recessive osteogenesis imperfecta. Calcif. Tissue Int. 93, 338-347 (2013).
102. Gebken, J., et al. Increased cell surface expression of receptors for transforming growth factor-β on osteoblasts from patients with Osteogenesis imperfecta. Pathobiology 68, 106-112 (2000).
103. Grafe, I., et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat. Med. 20, 670-675 (2014).
104. Lapunzina, P., et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am. J. Hum. Genet. 87, 110-114 (2010).
105. Keupp, K., et al. Mutations in WNT1 cause different forms of bone fragility. Am. J. Hum. Genet. 92, 565-574 (2013).
106. Laine, C. M., et al. WNT1 mutations in early-onset osteoporosis and osteogenesis imperfecta. N. Engl. J. Med. 368, 1809-1816 (2013).
107. Fahiminiya, S., et al. Whole-exome sequencing reveals a heterozygous LRP5 mutation in a 6-year-old boy with vertebral compression fractures and low trabecular bone density. Bone 57, 41-46 (2013).
108. Korvala, J., et al. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med. Genet. 13, 26 (2012).
109. Crabbe, P., et al. Missense mutations in LRP5 are not a common cause of idiopathic osteoporosis in adult men. J. Bone Miner. Res. 20, 1951-1959 (2005).
110. van Dijk, F. S., et al. PLS3 mutations in X-linked osteoporosis with fractures. N. Engl. J. Med. 369, 1529-1536 (2013).
111. Fahiminiya, S., et al. Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics. J. Bone Miner. Res. 29, 1805-1814 (2014).
112. Laine, C. M., et al. Primary osteoporosis without features of OI in children and adolescents: clinical and genetic characteristics. Am. J. Med. Genet. A 158A, 1252-1261 (2012).
113. Gong, Y., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-523 (2001).
114. Narumi, S., et al. Various types of LRP5 mutations in four patients with osteoporosis-pseudoglioma syndrome: identification of a 7.2-kb microdeletion using oligonucleotide tiling microarray. Am. J. Med. Genet. A 152A, 133-140 (2010).
115. Balemans, W. & Van Hul, W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology 148, 2622-2629 (2007).
116. Puig-Hervas, M. T., et al. Mutations in PLOD2 cause autosomal-recessive connective tissue disorders within the Bruck syndrome-osteogenesis imperfecta phenotypic spectrum. Hum. Mutat. 33, 1444-1449 (2012).
117. Shaheen, R., et al. Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans. Am. J. Med. Genet. A 155A, 1448-1452 (2011).
118. Schwarze, U., et al. Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. Hum. Mol. Genet. 22, 1-17 (2013).
119. Peacock, M., Turner, C. H., Econs, M. J. & Foroud, T. Genetics of osteoporosis. Endocr. Rev. 23, 303-326 (2002).
120. Siris, E. S., et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286, 2815-2822 (2001).
121. Duncan, E. L. & Brown, M. A. Clinical review 2: Genetic determinants of bone density and fracture risk-state of the art and future directions. J. Clin. Endocrinol. Metab. 95, 2576-2587 (2010).
122. Ralston, S. H. & Uitterlinden, A. G. Genetics of osteoporosis. Endocr. Rev. 31, 629-662 (2010).
123. Duncan, E. L., et al. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet. 7, e1001372 (2011).
124. Estrada, K., et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491-501 (2012).
125. Medina-Gomez, C., et al. Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet. 8, e1002718 (2012).
126. Richards, J. B., et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371, 1505-1512 (2008).
127. Rivadeneira, F., et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet. 41, 1199-1206 (2009).
128. Styrkarsdottir, U., et al. Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med. 358, 2355-2365 (2008).
129. Styrkarsdottir, U., et al. European bone mineral density loci are also associated with BMD in East-Asian populations. PLoS ONE 5, e13217 (2010).
130. Zhang, L., et al. Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum. Mol. Genet. 23, 1923-1933 (2014).
131. Moayyeri, A., et al. Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Hum. Mol. Genet. 23, 3054-3068 (2014).
132. Oei, L., et al. Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. Bone 59, 20-27 (2014).
133. Oei, L., et al. A genome-wide copy number association study of osteoporotic fractures points to the 6p25.1 locus. J. Med. Genet. 51, 122-131 (2014).
134. Chew, S., et al. Homozygous deletion of the UGT2B17 gene is not associated with osteoporosis risk in elderly Caucasian women. Osteoporos. Int. 22, 1981-1986 (2011).
135. Deng, F. Y., et al. Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in Caucasians. Osteoporos. Int. 21, 579-587 (2010).
136. Yang, T. L., et al. Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. Am. J. Hum. Genet. 83, 663-674 (2008).
137. Holroyd, C., Harvey, N., Dennison, E. & Cooper, C. Epigenetic influences in the developmental origins of osteoporosis. Osteoporos. Int. 23, 401-410 (2012).
138. Vrtacnik, P., Marc, J. & Ostanek, B. Epigenetic mechanisms in bone. Clin. Chem. Lab. Med. 52, 589-608 (2014).
139. Delgado-Calle, J., Garmilla, P. & Riancho, J. A. Do epigenetic marks govern bone mass and homeostasis? Curr. Genomics 13, 252-263 (2012).
140. Cohen-Kfir, E., et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology 152, 4514-4524 (2011).
141. Redfern, A. D., et al. RNA-induced silencing complex (RISC) proteins PACT, TRBP, and Dicer are SRA binding nuclear receptor coregulators. Proc. Natl Acad. Sci. USA 110, 6536-6541 (2013).
142. van Wijnen, A. J., et al. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis. Curr. Osteoporos. Rep. 11, 72-82 (2013).
143. Gamez, B., Rodriguez-Carballo, E. & Ventura, F. MicroRNAs and post-transcriptional regulation of skeletal development. J. Mol. Endocrinol. 52, R179-197 (2014).
144. Delgado-Calle, J., et al. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. J. Bone Miner. Res. 27, 926-937 (2012).
145. Delgado-Calle, J., et al. Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. Epigenetics 7, 83-91 (2012).
146. Gelb, B. D., Shi, G. P., Chapman, H. A., & Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273, 1236-1238 (1996).
147. Fijalkowski, I., Boudin, E., Mortier, G. & van Hul, W. Sclerosing bone dysplasias: leads toward novel osteoporosis treatments. Curr. Osteoporos. Rep. 12, 243-251 (2014).
148. Tella, S. H. & Gallagher, J. C. Biological agents in management of osteoporosis. Eur. J. Clin. Pharmacol. (2014).
149. McClung, M. R., et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412-420 (2014).
150. Recker, R., et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J. Bone Miner. Res. 30, 216-224 (2015).